Ozmosi | Lapatinib Drug Profile

Product Description

Lapatinib is a small molecule inhibitor of several tyrosine kinase receptors involved in tumor cell growth that is used in the therapy of advanced breast cancer and other solid tumors. Lapatinib therapy is associated with transient elevations in serum aminotransferase levels and rare instances of clinically apparent acute liver injury. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Lapatinib)

Mechanisms of Action: HER2 Inhibitor, EGFR Inhibitor, TK Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Approved

Approved Indications: None

Known Adverse Events: None

Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lapatinib

Countries in Clinic: China, United States

Active Clinical Trial Count: 6

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Adenocarcinoma|Breast Cancer|Esophageal Cancer|Gastrointestinal Cancer

Phase 2: Glioblastoma|Intestinal Cancer|Non-Small-Cell Lung Cancer

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
2018-002190-21	ROME	P2	Completed	Breast Cancer\|Intestinal Cancer\|Non-Small-Cell Lung Cancer	2024-09-06		2025-05-06	Primary Completion Date\|Study Completion Date\|Treatments\|Trial Status
NCT01591577	NCT01591577	P2	Completed	Glioblastoma	2024-05-07	30%	2024-05-17	Primary Endpoints
2007-005725-29	2007-005725-29	P3	Completed	Gastrointestinal Cancer\|Adenocarcinoma\|Esophageal Cancer	2024-10-03	39%	2025-05-06	Primary Completion Date\|Study Completion Date\|Treatments\|Trial Status
2013-005044-29	TYPHER (TYverb Plus HERceptin in metastatic breast cancer)	P2	Completed	Breast Cancer	2024-08-09		2025-05-06	Primary Completion Date\|Study Completion Date\|Treatments\|Trial Status
CTR20161036	CTR20161036	P2	Recruiting	Breast Cancer	None		2025-04-29
CTR20170095	CTR20170095	P3	Completed	Breast Cancer	2023-11-14		2025-04-29	Patient Enrollment\|Primary Completion Date\|Study Completion Date

Recent News Events

Date	Type	Title
02/11/2025	News Article	New Breast Cancer Therapy to Reduce Risk of Recurrence and Improve Disease-Free Survival Now Approved in Thailand
12/12/2024	News Article	2024 SABCS｜Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer with Liver Metastasis
07/11/2024	News Article	Head and Neck Cancer Treatment Market size is set to grow by USD 7.12 billion from 2024-2028, Increasing incidence of head and neck cancers boost the market, Technavio
07/03/2024	News Article	McGill, industry, CQDM and Brain Canada collaborate for drug discovery

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Lapatinib

Alternative Names: lapatinib, tykerb, gw572016, tyverb Clinical Status: Inactive Latest Update: 2025-08-15 Latest Update Note: Clinical Trial Update